The most read articles of january in solaci.org

These were the most read articles of interventional cardiology in solaci.org. Real-World Revascularization Strategy for Left Main Coronary Artery: Surgery or PCI? There are many current randomized trials comparing percutaneous coronary intervention (PCI) with myocardial revascularization surgery (MRS) for the treatment of left main coronary artery disease (LMCAD). Real-World Results of Different Devices for TAVR Transcatheter aortic valve replacement (TAVR) keeps<a href="https://solaci.org/en/2023/02/06/the-most-read-articles-of-january-in-solaci-org/" title="Read more" >...</a>

Buen desempeño de la Sapien 3 en “trabajos” para los que no está diseñada

Real-World Results of Different Devices for TAVR

Transcatheter aortic valve replacement (TAVR) keeps growing in terms of the development of new devices, more extensive operator experience, and enhanced procedure planning. Nowadays, there are multiple device options, which depend on patient characteristics and operator experience. Two-arm studies compared these devices, analyzing the potential benefits of a certain valve over the others. This multicenter<a href="https://solaci.org/en/2023/01/04/real-world-results-of-different-devices-for-tavr/" title="Read more" >...</a>

Nuevas guías de valvulopatías con actualizaciones clave en TAVI e insuficiencia mitral

SURTAVI at 5 Years

Transcatheter aortic valve replacement (TAVR) by transfemoral access has shown great benefit for different risk groups, but its long-term durability is still uncertain. Available evidence comes from small analysis and a single randomized trial with 280 patients and an 8 year follow-up: the NOTION Trial, where TAVR showed less valvular degeneration than aortic valve replacement (AVR) surgery.<a href="https://solaci.org/en/2022/10/17/surtavi-at-5-years/" title="Read more" >...</a>

ATC sobre arterias nativas o puentes venosos, ¿cuál tiene mejor pronóstico?

Tricuspid Regurgitation: Edge-to-Edge Treatment with PASCAL

About 4% of the population suffers from tricuspid regurgitation (TR). This disease is associated with hard-to-manage heart failure (HF)—often requiring hospitalization—and with mortality. Surgery in this valve is not simple and has high morbidity and mortality rates due to its comorbidities. Currently, a percutaneous strategy for its resolution is under development, but we still do<a href="https://solaci.org/en/2022/07/21/tricuspid-regurgitation-edge-to-edge-treatment-with-pascal/" title="Read more" >...</a>

La enfermedad vascular periférica se asocia a más eventos en el TAVI

TAVR, More Information Supports Its Use

TAVR has been reported beneficial in the treatment of high and intermediate risk patients but, initially, randomized clinical trials have shown vascular complication and pacemaker implantation rates higher than SAVR in low-risk patients. This will most certainly improve as operator experience and device development advance. This is a randomized 1:1 study including 458 patients receiving<a href="https://solaci.org/en/2022/06/09/tavr-more-information-supports-its-use/" title="Read more" >...</a>

New-Generation ACURATE Neo2

Transcatheter aortic valve replacement (TAVR) is a therapeutical option for patients with symptomatic severe aortic stenosis. Current guidelines recommend TAVR in patients ≥75 years with intermediate risk. One of the most frequent complications of this procedure is moderate or greater aortic regurgitation (AR) after implantation. Consequently, new valves have been developed to try and reduce<a href="https://solaci.org/en/2022/06/03/new-generation-acurate-neo2/" title="Read more" >...</a>

TAVR: If Not Transfemoral, We Should Consider Transcaval Access

Transcatheter aortic valve replacement (TAVR) through transfemoral access has already proven its great benefits, but this access cannot be used in certain patients, and alternative accesses need to be considered for such cases. One of the most commonly used accesses is the transaxillary or transubclavian access (AX), which, however, is associated with more complications (especially<a href="https://solaci.org/en/2022/06/01/tavr-if-not-transfemoral-we-should-consider-transcaval-access/" title="Read more" >...</a>

The most read scientific papers of September in interventional cardiology

01- ESC 2021 | Updated European Society of Cardiology Guidelines for the Management of Valvular Heart Disease Early intervention in asymptomatic valvular heart disease, age recommendations to decide between TAVR and surgery for aortic stenosis, and a push in favor of transcatheter repair in secondary mitral regurgitation are some of the new modifications to the European<a href="https://solaci.org/en/2021/10/01/the-most-read-scientific-papers-of-september-in-interventional-cardiology/" title="Read more" >...</a>

SOLACI/SIAC Latin American Clinical Guidelines on TAVR vs. SAVR Published

The Latin American Society of Interventional Cardiology is proud to announce that the Latin American Clinical Guidelines on TAVR vs. SAVR on patients with severe aortic stenosis have been published. This high-quality scientific work was published in the Heart BMJ Journal and is the result of an arduous joint effort between SOLACI (through its Research<a href="https://solaci.org/en/2021/06/16/solaci-siac-latin-american-clinical-guidelines-on-tavr-vs-savr-published/" title="Read more" >...</a>

Sangrados mayores en pacientes con AAS más rivaroxabán

AAS vs DAPT post TAVI: Meta-Analysis of Randomized Studies

Aspirin monotherapy (ASA) reduced the combined risk of thrombotic and bleeding events compared against dual antiplatelet therapy (DAPT) in patients receiving transcatheter aortic valve replacement (TAVR). This meta-analysis has only reproduced smaller randomize study outcomes and does not include the OCEAN-TAVI registry, the only one that has shown something different so far.  Even though ASA<a href="https://solaci.org/en/2021/06/14/aas-vs-dapt-post-tavi-meta-analysis-of-randomized-studies/" title="Read more" >...</a>

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31